Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Revive Rx LLC dba Revive Rx Pharmacy
WARNING LETTER
•Revive Rx LLC dba Revive Rx Pharmacy•February 7, 2025

Revive Rx LLC dba Revive Rx Pharmacy – FDA Warning Letter, Feb 7, 2025

Record Details

The FDA issued a Warning Letter to Revive Rx LLC dba Revive Rx Pharmacy following an inspection conducted from January 27 to February 7, 2025. The inspection revealed serious deficiencies in the company"s drug product production practices, particularly concerning sterile preparations, which put patients at risk. The main violations included insanitary conditions that led to adulterated drug products under sections 501(a)(2)(A), 301(a), and 301(k) of the Federal Food, Drug, and Cosmetic Act (FDCA). Specific issues observed were exposing sterile drug products to sub-standard air quality, inadequate responses to microbial contamination in aseptic areas, media fills not performed under challenging conditions, insufficient smoke studies, failure to properly sterilize components, and inadequate routine environmental monitoring. While Revive Rx submitted corrective action plans, the FDA deemed several responses deficient. The agency cited a lack of interim measures to protect products, incomplete investigations into contamination events, and insufficient documentation or clarification regarding how fundamental issues, such as media fills and sterilization processes, would be immediately rectified. The FDA requires comprehensive and documented corrective actions to ensure patient safety and compliance.

Company
Revive Rx LLC dba Revive Rx Pharmacy
Inspection date
February 7, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Aaron M. Schneider
  • F. Gail Bormel (F.)
  • Lawerence T. Bonk
View Company Profile

ID · 95af4bc5-dbe9-4cf0-9f12-326c692062d0

Violation Codes10
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)FD&C Act 50521.U.S.C. 331(a)21.U.S.C. 355(a)FD&C Act 301(k)FD&C Act 502(f)(1)FD&C Act 501(a)(2)(A)21 U.S.C. 331(k)21 U.S.C. 352(f)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Revive Rx LLC dba Revive Rx Pharmacy
  • 483 - 2026-03-27March 27, 2026
  • 483 - 2025-02-07February 7, 2025
  • UNTITLED_LETTER - 2023-06-30June 30, 2023
  • 483 - 2022-05-04May 4, 2022
  • 483 - 2021-08-06August 6, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Revive Rx LLC dba Revive Rx Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.